Healthcare provider profile · identity verified

John C Simmons, MD

Allopathic & Osteopathic Physicians|General Practice · LINDEN, AL · NPI 1104832724

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show John C Simmons, MD received $105.92 in general payments during 2025 across 6 reported records.

Novo Nordisk Inc accounted for 78.1% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Linzess by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Ozempic by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Rybelsus by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$105.92

6 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$82.75	78.1%	5	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$23.17	21.9%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$105.92	6

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Wegovy Normalized: wegovy	Drug	Novo Nordisk Inc	$68.52	4	2025
Source payment records 2025-02-21 · Novo Nordisk Inc · $17.80 · Open Payments source 2025-04-02 · Novo Nordisk Inc · $14.41 · Open Payments source 2025-06-25 · Novo Nordisk Inc · $19.21 · Open Payments source 2025-10-14 · Novo Nordisk Inc · $17.10 · Open Payments source
VRAYLAR Normalized: vraylar	Drug	ABBVIE INC.	$23.17	1	2025
Source payment records 2025-05-08 · ABBVIE INC. · $23.17 · Open Payments source
Ozempic Normalized: ozempic	Drug	Novo Nordisk Inc	$14.23	1	2025
Source payment records 2025-09-04 · Novo Nordisk Inc · $14.23 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
Ozempic ozempic	2025	Ozempic	2024	126	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	LINZESS open payments reported associated product	CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608	Linzess · 2024 Exact normalized brand match · 1 Part D row	72	20
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	SYNTHROID open payments reported associated product	CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636	Synthroid · 2024 Exact normalized brand match · 1 Part D row	31	suppressed by CMS
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	126	19
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Rybelsus open payments reported associated product	CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076	Rybelsus · 2024 Exact normalized brand match · 1 Part D row	40	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Gabapentin	Gabapentin	703	120
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	635	77
Amlodipine Besylate	Amlodipine Besylate	614	164
Omeprazole	Omeprazole	580	119
Tramadol Hcl	Tramadol Hcl	501	83
Losartan Potassium	Losartan Potassium	493	113
Atorvastatin Calcium	Atorvastatin Calcium	479	75
Furosemide	Furosemide	422	74
Potassium Chloride	Potassium Chloride	411	73
Levothyroxine Sodium	Levothyroxine Sodium	410	78
Rosuvastatin Calcium	Rosuvastatin Calcium	381	98
Alprazolam	Alprazolam	353	47
Pantoprazole Sodium	Pantoprazole Sodium	338	72
Hydrochlorothiazide	Hydrochlorothiazide	314	69
Escitalopram Oxalate	Escitalopram Oxalate	296	65
Fluticasone Propionate	Fluticasone Propionate	273	93
Carvedilol	Carvedilol	270	55
Trazodone Hcl	Trazodone Hcl	251	60
Tizanidine Hcl	Tizanidine Hcl	247	53
Allopurinol	Allopurinol	230	30
Lisinopril	Lisinopril	224	56
Metoprolol Tartrate	Metoprolol Tartrate	218	41
Metformin Hcl	Metformin Hcl	215	52
Eliquis	Apixaban	185	31
Mounjaro	Tirzepatide	174	27
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	165	65
Albuterol Sulfate Hfa	Albuterol Sulfate	164	61
Simvastatin	Simvastatin	164	31
Pravastatin Sodium	Pravastatin Sodium	163	18
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	153	19
Lorazepam	Lorazepam	151	23
Hydralazine Hcl	Hydralazine Hcl	142	29
Tamsulosin Hcl	Tamsulosin Hcl	141	33
Buspirone Hcl	Buspirone Hcl	126	24
Ozempic	Semaglutide	126	19
Famotidine	Famotidine	125	21
Azithromycin	Azithromycin	123	99
Montelukast Sodium	Montelukast Sodium	123	23
Donepezil Hcl	Donepezil Hcl	122	16
Duloxetine Hcl	Duloxetine Hcl	120	26
Metoprolol Succinate	Metoprolol Succinate	117	36
Metformin Hcl Er	Metformin Hcl	115	32
Pregabalin	Pregabalin	114	17
Sertraline Hcl	Sertraline Hcl	107	16
Quetiapine Fumarate	Quetiapine Fumarate	103	15
Clonidine Hcl	Clonidine Hcl	100	33
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	100	27
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	100	27
Celecoxib	Celecoxib	98	35
Xarelto	Rivaroxaban	98	suppressed
Glipizide	Glipizide	97	26
Meloxicam	Meloxicam	94	25
Oxycodone Hcl	Oxycodone Hcl	94	suppressed
Amoxicillin	Amoxicillin	91	61
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	89	11
Clonazepam	Clonazepam	83	12
Fluconazole	Fluconazole	82	37
Colchicine	Colchicine	80	17
Zolpidem Tartrate	Zolpidem Tartrate	80	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	77	20
Memantine Hcl	Memantine Hcl	74	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	72	suppressed
Linzess	Linaclotide	72	20
Myrbetriq	Mirabegron	72	suppressed
Levetiracetam	Levetiracetam	71	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	70	suppressed
Topiramate	Topiramate	70	suppressed
Clopidogrel	Clopidogrel Bisulfate	69	18
Mirtazapine	Mirtazapine	68	12
Ibuprofen	Ibuprofen	67	32
Latanoprost	Latanoprost	67	suppressed
Methocarbamol	Methocarbamol	67	25
Acetaminophen-Codeine	Acetaminophen With Codeine	66	19
Meclizine Hcl	Meclizine Hcl	65	20
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	65	48
Hydroxyzine Hcl	Hydroxyzine Hcl	64	19
Methylprednisolone	Methylprednisolone	63	47
Alendronate Sodium	Alendronate Sodium	62	21
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	62	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	61	47
Glimepiride	Glimepiride	61	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	61	17
Promethazine Hcl	Promethazine Hcl	58	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	57	15
Nitrofurantoin	Nitrofurantoin Macrocrystal	57	44
Sucralfate	Sucralfate	57	15
Ropinirole Hcl	Ropinirole Hcl	56	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	55	38
Ezetimibe	Ezetimibe	55	19
Warfarin Sodium	Warfarin Sodium	55	suppressed
Entresto	Sacubitril/Valsartan	53	suppressed
Ondansetron Hcl	Ondansetron Hcl	53	20
Phenytoin	Phenytoin	53	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	52	suppressed
Diclofenac Sodium	Diclofenac Sodium	51	15
Gemtesa	Vibegron	51	16
Constulose	Lactulose	47	suppressed
Ofloxacin	Ofloxacin	47	34
Mupirocin	Mupirocin	46	25
Olmesartan Medoxomil	Olmesartan Medoxomil	46	suppressed
Ondansetron Odt	Ondansetron	46	27
Amitriptyline Hcl	Amitriptyline Hcl	43	suppressed
Bupropion Xl	Bupropion Hcl	43	11
Cyproheptadine Hcl	Cyproheptadine Hcl	43	18
Esomeprazole Magnesium	Esomeprazole Magnesium	43	suppressed
Irbesartan	Irbesartan	43	suppressed
Lovastatin	Lovastatin	43	suppressed
Spironolactone	Spironolactone	43	11
Farxiga	Dapagliflozin Propanediol	42	11
Tresiba Flextouch U-100	Insulin Degludec	42	12
Ramipril	Ramipril	41	suppressed
Rybelsus	Semaglutide	40	suppressed
Levofloxacin	Levofloxacin	39	24
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	39	36
Bumetanide	Bumetanide	38	11
Doxazosin Mesylate	Doxazosin Mesylate	38	11
Metolazone	Metolazone	38	suppressed
Risperidone	Risperidone	37	suppressed
Baclofen	Baclofen	36	suppressed
Lansoprazole	Lansoprazole	36	suppressed
Pentoxifylline	Pentoxifylline	35	suppressed
Tresiba Flextouch U-200	Insulin Degludec	35	suppressed
Trulicity	Dulaglutide	35	suppressed
Labetalol Hcl	Labetalol Hcl	34	suppressed
Rizatriptan	Rizatriptan Benzoate	34	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	33	suppressed
Januvia	Sitagliptin Phosphate	33	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	33	suppressed
Buprenorphine Hcl	Buprenorphine Hcl	31	suppressed
Estradiol	Estradiol	31	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	31	11
Jardiance	Empagliflozin	31	11
Synthroid	Levothyroxine Sodium	31	suppressed
Benazepril Hcl	Benazepril Hcl	30	suppressed
Nifedipine Er	Nifedipine	30	suppressed
Theophylline Er	Theophylline Anhydrous	30	suppressed
Lactulose	Lactulose	29	suppressed
Symbicort	Budesonide/Formoterol Fumarate	29	suppressed
Midodrine Hcl	Midodrine Hcl	27	suppressed
Chlorthalidone	Chlorthalidone	26	suppressed
Colesevelam Hcl	Colesevelam Hcl	26	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	26	suppressed
Novolog	Insulin Aspart	26	suppressed
Tradjenta	Linagliptin	26	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	26	12
Zafirlukast	Zafirlukast	26	suppressed
Zenpep	Lipase/Protease/Amylase	26	suppressed
Acarbose	Acarbose	25	suppressed
Mometasone Furoate	Mometasone Furoate	25	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	24	suppressed
Jantoven	Warfarin Sodium	24	suppressed
Naproxen	Naproxen	24	12
Novolog Flexpen	Insulin Aspart	24	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	24	suppressed
Paliperidone Er	Paliperidone	24	suppressed
Ventolin Hfa	Albuterol Sulfate	24	suppressed
Diazepam	Diazepam	23	suppressed
Lamotrigine	Lamotrigine	23	suppressed
Nystatin	Nystatin	23	14
Temazepam	Temazepam	23	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	23	suppressed
Atenolol	Atenolol	22	suppressed
Humalog Kwikpen U-100	Insulin Lispro	22	suppressed
Humulin R	Insulin Regular, Human	22	suppressed
Rasagiline Mesylate	Rasagiline Mesylate	22	suppressed
Timolol Maleate	Timolol Maleate	22	suppressed
Diclofenac Potassium	Diclofenac Potassium	21	suppressed
Humalog	Insulin Lispro	21	suppressed
Fenofibrate	Fenofibrate	20	suppressed
Ketoconazole	Ketoconazole	20	suppressed
Metronidazole	Metronidazole	20	15
Terbinafine Hcl	Terbinafine Hcl	20	suppressed
Finasteride	Finasteride	19	suppressed
Ibu	Ibuprofen	19	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	19	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	18	suppressed
Diltiazem Hcl	Diltiazem Hcl	18	suppressed
Hydrocortisone	Hydrocortisone	18	suppressed
Prednisone	Prednisone	18	16
Valsartan	Valsartan	18	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	17	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	17	suppressed
Amiodarone Hcl	Amiodarone Hcl	16	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Divalproex Sodium	Divalproex Sodium	16	suppressed
Invokana	Canagliflozin	16	suppressed
Ketorolac Tromethamine	Ketorolac Tromethamine	16	suppressed
Paroxetine Hcl	Paroxetine Hcl	16	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Ursodiol	Ursodiol	16	suppressed
Acyclovir	Acyclovir	15	suppressed
Gemfibrozil	Gemfibrozil	15	suppressed
Levemir Flexpen	Insulin Detemir	15	suppressed
Medroxyprogesterone Acetate	Medroxyprogesterone Acetate	15	suppressed
Nyamyc	Nystatin	15	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	15	suppressed
Prednisolone Acetate	Prednisolone Acetate	15	suppressed
Raloxifene Hcl	Raloxifene Hcl	15	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	15	suppressed
Clobetasol Propionate	Clobetasol Propionate	14	suppressed
Glipizide Er	Glipizide	14	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	14	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	14	suppressed
Ulticare Pen Needle	Pen Needle, Diabetic	14	suppressed
Albuterol Sulfate	Albuterol Sulfate	13	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	13	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	13	suppressed
Dutasteride	Dutasteride	13	suppressed
Fycompa	Perampanel	13	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	13	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Oxycontin	Oxycodone Hcl	13	suppressed
Methadone Hcl	Methadone Hcl	12	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	12	suppressed
Flecainide Acetate	Flecainide Acetate	11	suppressed
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	11	suppressed
Oseltamivir Phosphate	Oseltamivir Phosphate	11	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	11	suppressed
Testosterone Cypionate	Testosterone Cypionate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$105.92 · 6 records	Novo Nordisk Inc	Ozempic, VRAYLAR, Wegovy	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Ozempic play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error